HYD.ASX: Remedy Robotics awards HYD A$3.4M Surgical Robotics Contract

Remedy Robotics awards HYD A$3.4M Surgical Robotics Contract

Stock	HYDRIX Ltd (HYD.ASX)
Release Time	20 Jul 2026, 9:29 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

HYD Secures A$3.4M Medical Robotics Contract with Remedy Robotics

Key Points

HYD awarded A$3.4M contract by Remedy Robotics
Contract involves developing software and electronics for N1 robotic platform
Expected to generate revenue in FY2027, over 50% of HYD's market cap

Full Summary

HYDRIX Limited (ASX: HYD) has secured a significant A$3.4 million engineering development contract with US-based Remedy Robotics. This contract involves the development of safety-critical software and embedded electronics for Remedy's next-generation N1 robotic platform for endovascular intervention. The contract reinforces HYD's position as a specialist engineering partner in advanced medical robotics, a rapidly growing segment of the global medical technology industry. Based on the agreed scope of work, to be undertaken on a time-and-materials basis, HYD expects the contract to generate approximately A$3.4 million in revenue. Revenue will be recognised progressively in FY2027 and is expected to be over 50% of HYD's current market capitalisation.

Guidance

Expected A$3.4M revenue in FY2027

Outlook

The contract is expected to significantly expand HYD's engineering support for Remedy's N1 system, accelerating platform maturity for future clinical studies.